| Literature DB >> 32709926 |
Abstract
T lymphocytes comprise cells expressing either an αβ or a γδ TCR. The riddle how αβ TCRs are triggered by specific peptides presented in the context of MHC was elucidated some time ago. In contrast, the mechanisms that underlie antigen recognition by γδ TCRs are still baffling the scientific community. It is clear that activation of γδ TCRs does not necessarily depend on MHC antigen presentation. To date, diverse and largely host-cell-derived molecules have been identified as cognate antigens for the γδ TCR. However, for most γδ TCRs, the activating ligand is still unknown and many open questions with regard to physiological relevance and generalizable concepts remain. Especially the question of how γδ T cells can distinguish homeostatic from stress conditions via their TCR remains largely unresolved. Recent discoveries in the field might have paved the way towards a better understanding of antigen recognition by the γδ TCR and have made it conceivable to revise the current knowledge and contextualize the new findings.Entities:
Keywords: antigen recognition; gamma-delta TCR; ligands
Year: 2020 PMID: 32709926 PMCID: PMC7608190 DOI: 10.1038/s41423-020-0503-y
Source DB: PubMed Journal: Cell Mol Immunol ISSN: 1672-7681 Impact factor: 11.530
List antigens for the γδ TCR
| Name | Species | TCR V-usage | Affinity | Comments | Reference |
|---|---|---|---|---|---|
| I-Eb, k, s | Mouse | Vγ1+/Vγ2 + | >240 µM (estimated) | [ | |
| H-2k, b, f, q, s | Mouse | Vγ2Vα11 | N.D. | [ | |
| HLA-A24 | Human | Vδ1+ | N.D. | Allo-HLA recognition | [ |
| HLA-B27-ci | Human | Vγ4Vδ1 | N.D. | Allo-HLA recognition | [ |
| HLA-A2 | Human | Vδ1+ | N.D. | Allo-HLA recognition | [ |
| HLA-A∗24:2 | Human | Vγ5Vδ1 | N.D. | Allo-HLA recognition but peptide loading required for increased stability of MHC | [ |
| HLA-A2/MART-1 | Human | Vδ1+ | 2.9–71 µM | Response restricted to MHC-presented MART-1 peptide | [ |
| CD1-d | Human/Mouse | Vδ1+/Vδ3+ | 16–33 µM | Affinity higher upon lipid-antigen presentation but binding also to non-presenting CD1-d | [ |
| CD1-c | Human | Vδ1+ | 23–125 µM | Affinity higher upon lipid-antigen presentation but binding also to non-presenting CD1-c | [ |
| Qa-1b/Glu50Tyr50 | Mouse | N.D. | N.D. | Unclear, if antigen is presented or not | [ |
| MR-1 | Human | Vδ1+ | 2.7–30.6 µM | No specificity for presented antigens | [ |
| EPCR | Human | Vγ4Vδ5 | 90 µM | Generation of blocking antibody to identify antigen | [ |
| MICA | Human | Vδ1+ | 110–900 µM | High-affinity NKG2D-ligand | [ |
| ULBP4 | Human | Vγ9Vδ2 | N.D., but direct interaction shown by ELISA | High-affinity NKG2D-ligand | [ |
| T10/T22 | Mouse | Diverse/clones G8 (Vγ4δ5) and KN6 (Vγ4δ10) | 0.1 µM | Used for generation of γδ TCR-transgenic mice with defined specificity | [ |
| Annexin A2 | Human | Vγ8Vδ3 | 3 µM | Generation of blocking antibody to identify antigen | [ |
| EphA2 | Human | Vγ9Vδ1 | N.D. | γδ TCR activation only if EphA2 is bound to ephrins on γδ T cell | [ |
| hMSH2 | Human | Vδ2+ | N.D. | High-affinity NKG2D-ligand | [ |
| Histidyl tRNA synthetase | Human | Vγ3Vδ2 | N.D. | Cell surface exposition not shown | [ |
| HSV-gI | Mouse | Vγ2Vδ8 | N.D. | Conformational epitope at N-terminus of HSV-gI | [ |
| SEA | Human | Vγ9+ (cytotoxic response), Vγ9− (cytotoxic response and proliferation) | N.D. | Superantigen from | [ |
| OXYS | Human | Vγ9Vδ2 | N.D. | Superantigen from Bacillus Calmette-Guérin | [ |
| DX2 | Human | Vγ9Vδ2 | N.D. | Superantigen from | [ |
| Phycoerythrin (PE) | Human, Mouse, Ruminants | Human: Vγ1Vδ1 Mouse: Vγ1+/Vγ4+ (Spleen), Vγ7+ (intestine) | 2.69 µM (Mouse) | No physiological antigen, protein from red algae | [ |
| Cy3 | Mouse | Vγ1+/Vγ4+ | 78.2 nM | Hapten, no physiological antigen | [ |
| 4-hydroxy-3-nitrophenyl acetyl (NP) | Mouse | Vγ1+ | 660 nM | Hapten, no physiological antigen | [ |
| Insulin peptide B:9–23 | Mouse | Vγ1+ (without immunization), Vγ4+ (if immunized with peptide) | N.D. | Response idependent of APCs | [ |
| HSP-60 peptide | Mouse | Vγ1+ | N.D. | Peptides of mycobacterial and mammalian origin recognized | [ |
| Peptide from Listeriolysin O | Human | N.D. | N.D. | [ | |
| Peptide from Tetanus toxin | Human | Vγ9Vδ2 | N.D. | Presented by HLA-DRw53 | [ |
| Ig λ-chain | Human | N.D. | N.D. | Recognition if antigen is not on cell surface; presentation mechanism involved? | [ |
| Polyanionic molecules | Mouse | Vγ1Vδ6.3 | N.D. | Response independent of APCs | [ |
| BTN3A1 | Human | Vγ9Vδ2 | N.D. | Required for phosphoantigen response, binds phosphoantigen intracellularly, no direct interaction with γδ TCR shown to date | [ |
| BTN2A1 | Human | Vγ9Vδ2 | 40–50 µM | Required for phosphoantigen response, Interaction with Vγ9-chain via HV4 and CDR2 | [ |
| Skint-1 | Mouse | Vγ5Vδ1 (DETC) | N.D. | Butyrophilin-like molecule required for homing of Vγ5Vδ1+ DETCs, direct interaction with γδ TCR not shown | [ |
| BTNL3 | Human | Vγ4+ | SPR: 20.7 µM, ITC: 3.5 µM | Heterodimer with BTNL8, interaction via HV4 and CDR2 of γ-chain, required probably for tissue homing and homeostasis | [ |
| Btnl6 | Mouse | Vγ7+ | N.D. | Heterodimer with Btnl6, mouse homologue of BTNL3, interaction via HV4 and CDR2 of γ-chain, required probably for tissue homing and homeostasis | [ |
Fig. 1Mechanisms for the discrimination of health and stress conditions via the γδ TCR. a The putative γδ TCR ligand might be differentially expressed depending on the stress level of the cell. In the case of stress-induced antigens such as Annexin A2 or MICA/MICB this would mean an upregulation whereas BTNL molecules might be downregulated allowing for γδ TCR activation via the CDR3. b Co-stimulatory molecules such as CD27 or JAML might be required for full activation of the γδ TCR and their upregulation might be triggered by stress conditions. c Changes in the conformation of the ligand might increase the accessibility of a particular γδ TCR binding domain. BTN3A1 for example undergoes conformational changes upon p-Ag binding. d Multimerization or monomerization of the respective ligand can be triggers for γδ TCR as in the case of the HLA-molecule A*24:02. e Glycosylation patterns are modified upon infections or tumor development. These changes in post-translational modifications might lead to different outcomes of γδ TCR interaction with the same ligand with different glycan residues on the extracellular domain